Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Sweden / NCT06926504
Recruiting Observational

TeamBirth-SWE - a Care Process to Improve Safe and Person-centered Intrapartum Care

NCT06926504 · tracked via the Priya Life Science Sweden tracker
Phase
Observational
Started
2024-02-05
Last updated
2025-04-13

Condition(s) studied

Person Centered CarePatient SafetyPatient Satisfaction

Investigational drug(s) / intervention(s)

The care process S-TeamBirthS-TeamBirth

The care process S-TeamBirth: The intervention consists of the entire care team conducting huddles together with the birthing woman and her partner to plan the care, using the S-TeamBirth whiteboard to communicate and visualize decisions

S-TeamBirth: Involving the entire care team including the woman and her partner in planning the care using team huddles and the S-TeamBirth whiteboard

Study summary

The primary objective of this project is to enhance understanding of intrapartum patient safety and person-centered care through the evaluation of an intervention designed to improve team communication and patient involvement during childbirth, thereby positively impacting maternal and infant health.

Despite various efforts to improve safety in intrapartum care, women and their infants are still harmed. Most adverse events within intrapartum care stem from communication and teamwork failures. Despite national and international recommendations, few interventions target patient safety by incorporating person-centered care.

This project will investigate the effectiveness and implementation of the TeamBirth care process developed by Ariadne Labs Boston, U.S. to improve communication and teamwork among caregivers and women during childbirth. The Swedish version of this care process (TeamBirth-SWE) was adapted, tested, and piloted at Karolinska University Hospital during 2021.

Hypothesis: We hypothesize that the TeamBirth-SWE intervention will have a positive impact on interprofessional teamwork, communication, information sharing, patient involvement, and shared decision-making during labor and birth. These improvements are expected to result in improved maternal and infant outcomes, process measures i.e., patient safety climate, interprofessional collaboration, and improved patient reported measures such as patient involvement, shared-decision-making, and satisfaction with care.

Eligibility

Sex
FEMALE
Min age
15 Years
Max age
—
Healthy volunteers
No
Inclusion criteria: * Spontaneous onset of labor * Induction of labort * Gestational week \>22+0 Exclusion criteria: * Planned cesarean section * Intrauterine Fetal Demise * Gestational week \<22+0, .

Primary outcome measure(s)

Trial sites (7)

FacilityCityRegionStatus
Region Halland, labour ward Halmstad, Halmstad Hospital Halmstad Halland County Recruiting
Region Halland, labour ward Varberg County Hospital Varberg Halland County Recruiting
Department of Women's Health, Labour ward Östersund County Hospital Östersund Region Jämtland Härjedalen Recruiting
Region Skåne, labour wards Lund & Malmö Lund Skåne County Recruiting
Department of Women's Health, labour ward Uppsala University Hospital Uppsala Uppsala County Recruiting
Department of Women's Health, Labour ward Karlstad County Hospital Karlstad Värmland County Recruiting
Department of Women's Health, Labour ward Solna & Huddinge, Karolinska University Hospital Stockholm Sweden Recruiting

More Karolinska Institutet trials in Sweden

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06926504 on ClinicalTrials.gov ↗ ← All trials in Sweden